Orca Bio

High-precision cell therapy to build a healthy immune system

First Investment: 2016

A stem cell transplant from a compatible donor is often the best hope for patients with leukemia and other cancers. But these treatments often come with long-lasting and even fatal side effects, such as graft-versus-host disease (GvHD). Orca Bio lowers the risk of GvHD by identifying the donor cells with real therapeutic benefits and screening out the rest, providing transplant recipients with a designer immune system.

News & Insights

DCVC Announcements

DCVC 2023 Q3 update: Climate Week NYC; deep tech and defense; geothermal groundbreaking; first humanoid robot factory; more

Life sciences and Deep Tech: The next set of solutions to the next set of problems

By Dr. Kiersten Stead, Dr. John Hamer, Matthew Ocko, Zachary Bogue

Explore Companies

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery

Latus Bio

Finding precisely tuned viral vectors for gene therapy in CNS disorders

Radionetics Oncology

Discovering more precise ways to deploy radiopharmaceuticals against solid tumors